Detection of African Swine Fever Virus Antibodies in Serum and Oral Fluid Specimens Using a Recombinant Protein 30 (p30) Dual Matrix Indirect ELISA

In the absence of effective vaccine(s), control of African swine fever caused by African swine fever virus (ASFV) must be based on early, efficient, cost-effective detection and strict control and elimination strategies. For this purpose, we developed an indirect ELISA capable of detecting ASFV anti...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 11; no. 9; p. e0161230
Main Authors Giménez-Lirola, Luis G, Mur, Lina, Rivera, Belen, Mogler, Mark, Sun, Yaxuan, Lizano, Sergio, Goodell, Christa, Harris, D L Hank, Rowland, Raymond R R, Gallardo, Carmina, Sánchez-Vizcaíno, José Manuel, Zimmerman, Jeff
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 09.09.2016
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In the absence of effective vaccine(s), control of African swine fever caused by African swine fever virus (ASFV) must be based on early, efficient, cost-effective detection and strict control and elimination strategies. For this purpose, we developed an indirect ELISA capable of detecting ASFV antibodies in either serum or oral fluid specimens. The recombinant protein used in the ELISA was selected by comparing the early serum antibody response of ASFV-infected pigs (NHV-p68 isolate) to three major recombinant polypeptides (p30, p54, p72) using a multiplex fluorescent microbead-based immunoassay (FMIA). Non-hazardous (non-infectious) antibody-positive serum for use as plate positive controls and for the calculation of sample-to-positive (S:P) ratios was produced by inoculating pigs with a replicon particle (RP) vaccine expressing the ASFV p30 gene. The optimized ELISA detected anti-p30 antibodies in serum and/or oral fluid samples from pigs inoculated with ASFV under experimental conditions beginning 8 to 12 days post inoculation. Tests on serum (n = 200) and oral fluid (n = 200) field samples from an ASFV-free population demonstrated that the assay was highly diagnostically specific. The convenience and diagnostic utility of oral fluid sampling combined with the flexibility to test either serum or oral fluid on the same platform suggests that this assay will be highly useful under the conditions for which OIE recommends ASFV antibody surveillance, i.e., in ASFV-endemic areas and for the detection of infections with ASFV isolates of low virulence.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors declare the following potential conflicts of interest with respect to the research authorship, and/or publication of this article: authors S. Lizano and C. Goodell are employed by IDEXX Laboratories, Inc. The remaining authors declare no conflicting interests with respect to their authorship or the publication of this article. The commercial affiliation above mentioned does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: LGGL JJZ.Performed the experiments: LGGL BR LM MM.Analyzed the data: YS LGGL JJZ.Contributed reagents/materials/analysis tools: LGGL LM SL CG MM DLH RRR JMS CG.Wrote the paper: LGGL JJZ.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0161230